| Title |
Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
|
|---|---|
| Published in |
British Journal of Cancer, November 2017
|
| DOI | 10.1038/bjc.2017.405 |
| Pubmed ID | |
| Authors |
Benjamin Daniels, Belinda E Kiely, Nehmat Houssami, Sarah J Lord, Timothy Dobbins, Christine Y Lu, Robyn L Ward, Sallie-Anne Pearson |
| Abstract |
Patients treated with (neo)adjuvant trastuzumab who relapse and receive trastuzumab for metastatic breast cancer (MBC) are a growing population with little outcome data given their exclusion from most clinical trials. We aim to estimate survival outcomes for this trastuzumab 'pre-treated' population. Population-based study of Australian women receiving trastuzumab for HER2-positive MBC between 2006 and 2014, who also received (neo)adjuvant trastuzumab. We used Kaplan-Meier methods to estimate the following: overall survival (OS) from initiation of trastuzumab for MBC; duration of trastuzumab for MBC; and time from last (neo)adjuvant trastuzumab to first trastuzumab for MBC. Of 3199 patients dispensed trastuzumab for MBC, 634 (20%) had received (neo)adjuvant traztuzumab. Pre-treated patients had a median (interquartile range) OS of 21.8 months (10.9-51.6), trastuzumab duration of 12.8 months (4.7-17.5), and time from last (neo)adjuvant trastuzumab to first trastuzumab for MBC of 15.6 months (6.5-28.6). Median OS for patients initiating trastuzumab <12 months and ⩾12 months from their last (neo)adjuvant trastuzumab were 17.1 months and 24.8 months, respectively. Patients starting trastuzumab for MBC following (neo)adjuvant trastuzumab had a median treatment duration of 1 year and OS of almost 2 years. These data help inform clinical practice and service planning for this under-researched population.British Journal of Cancer advance online publication, 14 November 2017; doi:10.1038/bjc.2017.405 www.bjcancer.com. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 17% |
| Student > Master | 6 | 13% |
| Other | 5 | 10% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Doctoral Student | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 15 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 17% |
| Nursing and Health Professions | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 16 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2017.
All research outputs
#13,573,145
of 23,007,887 outputs
Outputs from British Journal of Cancer
#8,698
of 10,478 outputs
Outputs of similar age
#164,218
of 325,276 outputs
Outputs of similar age from British Journal of Cancer
#69
of 89 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,478 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,276 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.